COL-3

Known as: COL 3, COL-3 compound 
A chemically-modified tetracycline with potential antineoplastic activity. COL-3 inhibits matrix metalloproteinases (MMPs), thereby inducing… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1988-2017
024619882017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
PURPOSE Matrix metalloproteinases (MMPs) are involved in tumor metastasis and are overexpressed in Kaposi's sarcoma (KS) cells… (More)
Is this relevant?
2006
2006
Tetracycline analogues (TCNAs) possess cytotoxic activities as well as matrix metalloproteinase (MMP) inhibitory properties… (More)
Is this relevant?
2006
2006
This phase II study evaluated the antitumor activity of the tetracycline analog COL-3, a potent inhibitor of metalloproteinases… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2004
2004
PURPOSE Overexpression of the proinflammatory enzyme cyclooxygenase (COX)-2 is associated with the progression of various… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2002
2002
PURPOSE Matrix metalloproteinases (MMPs) are involved in tumor invasion and metastasis and are overexpressed in Kaposi's sarcoma… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Antibiotic forms of tetracycline exhibit antitumor activity in some tumor models. However, their low in vivo efficacy and… (More)
Is this relevant?
2001
2001
PURPOSE This phase I clinical trial was designed to determine the maximum-tolerated dose and dose-limiting toxicities of the… (More)
Is this relevant?
2001
2001
Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia… (More)
Is this relevant?
2001
2001
Human matrix metalloproteinase-2 (MMP-2) contains an array of three fibronectin type II (FII) modules postulated to interact with… (More)
  • figure 1
  • figure 2
  • table I
  • figure 3
  • figure 4
Is this relevant?
2001
2001
BACKGROUND Anti-angiogenesis is an exciting new approach to anticancer therapy. COL-3, a tetracycline derivative, is a novel anti… (More)
Is this relevant?